This is a complete
list of , as well as drugs used to augment antidepressants, by pharmacological and/or structural classification. Chemical/generic names are listed first with brand names in parentheses. antidepressants Zimelidine (Normud, Zelmid) and indalpine (Upstene) were also formerly used as antidepressants, but were withdrawn from the market.
These drugs act as
serotonin reuptake inhibitors and agonize/ antagonize various serotonin receptors.
These drugs act as antagonists of various serotonin receptors and as weak serotonin reuptake inhibitors.
Nefazodone (Nefadar, Serzone) was also formerly used as an antidepressant, but was withdrawn from the market. Atomoxetine (Strattera) is also sometimes used as an antidepressant, but is not specifically approved for this purpose. Amitriptyline (Elavil, Endep) Amitriptylinoxide (Amioxid, Ambivalon, Equilibrin) Clomipramine (Anafranil) Desipramine (Norpramin, Pertofrane) Dibenzepin (Noveril, Victoril) Dosulepin (Prothiaden) Doxepin (Adapin, Sinequan) Imipramine (Tofranil) Lofepramine (Lomont, Gamanil) Melitracen (Dixeran, Melixeran, Trausabun) Nitroxazepine (Sintamil) Nortriptyline (Pamelor) Noxiptiline (Agedal, Elronon, Nogedal) Pipofezine (Azafen/Azaphen) Protriptyline (Vivactil) Trimipramine (Surmontil) Butriptyline (Evadyne), demexiptiline (Deparon, Tinoran), imipraminoxide (Imiprex, Elepsin), iprindole (Prondol, Galatur, Tetran), metapramine (Timaxel), propizepine (Depressin, Vagran), and quinupramine (Kinupril, Kevopril) were also formerly markted, but have since been discontinued.
The following are also TCAs, but are atypical pharmacologically:
Amineptine (Survector, Maneon) is another atypical TCA, acting as a norepinephrine-dopamine reuptake inhibitor (NDRI), but was withdrawn from the market. Tiazesim (Altinil) is not a TCA, but is a bicyclic antidepressant that is closely related structurally and pharmacologically. Similarly to many TCAs, it is no longer marketed.
Mianserin, mirtazapine, and setiptiline are also sometimes described as
(NaSSAs). noradrenergic and specific serotonergic antidepressants Irreversible [edit ] Non-selective [edit ]
Many others, including
benmoxin (Neuralex), iproclozide (Sursum), iproniazid (Marsilid), mebanazine (Actomol), nialamide (Niamid), octamoxin (Ximaol), pheniprazine (Catron), phenoxypropazine (Drazine), pivhydrazine (Tersavid), and safrazine (Safra) were used as antidepressants in the past, but have since been discontinued. Selective for MAO-B [edit ] Reversible [edit ] Non-selective [edit ] Caroxazone (Surodil, Timostenil) was formerly used as an antidepressant, but has been discontinued. Selective for MAO-A [edit ]
These drugs are sometimes described as
(RIMAs). reversible inhibitors of MAO-A Eprobemide (Befol) and minaprine (Brantur, Cantor) were also formerly used as antidepressants, but have been discontinued. Others [edit ] Marketed [edit ] Agomelatine (Valdoxan) – 5-HT 2C receptor antagonist and MT and 1 MT agonist; sometimes described as a 2 receptor (NDDI) norepinephrine-dopamine disinhibitor Amisulpride (Solian) – D, 2 D, and 3 5-HT antagonist – specifically approved for 7 receptor dysthymia Buprenorphine (Subutex, Temgesic, Buprenex) – κ-opioid receptor antagonist and μ-opioid receptor partial agonist – not specifically approved for depression (used off-label) Bupropion (Wellbutrin) – NRI and non-competitive antagonist of multiple neuronal nACh receptors Ketamine (Ketalar) – non-competitive NMDA receptor antagonist – not specifically approved for depression (used off-label) Lurasidone (Latuda) – 5-HT partial agonist, 1A receptor 5-HT, 5-HT 2 7, D 2, α, and 1-adrenergic α antagonist – specifically approved for 2-adrenergic receptor bipolar depression Tandospirone (Sediel) – 5-HT 1A receptor partial agonist Teniloxazine (Lucelan, Metatone) – NRI and 5-HT antagonist 2A receptor Discontinued/withdrawn from the market [edit ] Over-the-counter [edit ]
The following antidepressants are available both with a
prescription and over-the-counter: Adjunctive treatments [edit ]
This category includes drugs that are generally not considered to be significantly effective as treatments for depression alone, but have demonstrated effectiveness in the augmentation of other antidepressants.
Others [edit ] Combination products [edit ] Currently in clinical trials (investigational) [edit ] ALKS-5461 ( buprenorphine/ samidorphan) – κ-opioid receptor antagonist Amitifadine (DOV-21,947, EB-1010) – serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) Basimglurant (RG7090) – mGlu 5 receptor negative allosteric modulator CERC-301 (MK-0657) – NMDA receptor subunit 2B (NR2B) antagonist Decoglurant (RG1578) – mGlu and 2 mGlu negative allosteric modulator 3 receptor Esketamine – non-competitive NMDA receptor antagonist GLYX-13 – NMDA receptor glycine site partial agonist LY-2456302 – κ-opioid receptor antagonist NRX-1074 – NMDA receptor glycine site partial agonist NSI-189 – hippocampal neurotrophin; exact mechanism of action unknown RO4491533 – mGlu2 2 and mGlu 3 receptor negative allosteric modulator Tedatioxetine (Lu AA24530) – SNDRI and 5-HT 2A, 5-HT 2C, 5-HT, and 3 α antagonist 1A-adrenergic receptor Tramadol (ETS6103) – μ- and δ-opioid receptor agonist, serotonin releasing agent (SRA), NRI, 5-HT 2C receptor antagonist, NMDAR antagonist, α antagonist, 7 nAChR M and 1 M antagonist, and 3 receptor TRPV1 agonist See also [edit ] References [edit ]